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Background: Previous genome-wide association studies (GWAS) have identified a large number of genetic
variants for obesity and its related traits, representing a group of potential key genes in the etiology of
obesity. Emerging evidence suggests that epigenetics may play an important role in obesity. It has not
been explored whether the GWAS-identified loci contribute to obesity through epigenetics (e.g., DNA
(deoxyribonucleic acid) methylation) in addition to genetics. Method: A multi-stage cross-sectional study
was designed. We did a literature search and identified 117 genes discovered by GWAS for obesity and
its related traits. Then we analyzed whether the methylation levels of these genes were also associated
with obesity in two genome-wide methylation panels. We examined an initial panel of seven adolescent
obese cases and seven age-matched lean controls, followed by a second panel of 48 adolescent obese
cases and 48 age- and gender-matched lean controls. The validated CpG sites were further replicated in
two independent replication panels of youth (46 vs. 46 and 230 cases vs. 413 controls, respectively) and
a general population of youth, including 703 healthy subjects. Results: One CpG site in the lymphocyte
antigen 86 (LY86) gene, which showed higher methylation in the obese in both the initial (p = .009) and
second genome-wide DNA methylation panel (p = .008), was further validated in both replication panels
(meta p = .00016). Moreover, in the general population of youth, the methylation levels of this region
were significantly correlated with adiposity indices (p .02), insulin resistance (p = .001), and inflammatory
markers (p< .001). Conclusion: By focusing on recent GWAS findings in genome-wide methylation profiles,
we identified a solid association between LY86 gene DNA methylation and obesity.
 Keywords: DNA methylation, obesity, GWAS, insulin resistance, inflammation
Obesity is an important risk factor for various diseases, in-
cluding cardiovascular diseases (CVD) (Poirier et al., 2006),
type 2 diabetes (T2D; Wild et al., 2004), and certain types
of cancer (Anderson & Caswell, 2009). Its epidemic has im-
posed a huge burden on public health worldwide (Danaei
et al., 2009; Misra & Khurana, 2008). As a typical, com-
mon complex disease, obesity is the result of the interplay
between external (environmental) and internal (genetic)
factors (Catenacci et al., 2009). Recent fruitful genome-
wide association studies (GWAS) have identified a large
number of genetic variants contributing to obesity (Loos,
2012). However, a majority of these loci have only a small
effect on obesity susceptibility and explain just a fraction
of total variance (Loos, 2012). There is growing evidence
suggesting that epigenetics, a plastic and heritable (during
cell division) mechanism to record cues from external and
internal environments (Petronis, 2010) may play an im-
portant role in obesity (Drong et al., 2012; Feinberg et al.,
2010; Wang et al., 2010). It has not been explored if the
GWAS-identified loci contribute to obesity through epige-
netics (e.g., DNA (deoxyribonucleic acid) methylation) in
addition to genetics.
Taking advantage of our previous genome-wide methy-
lation profilings (Wang et al., 2010; Xu et al., 2013), the
current study focused on a group of candidate genes iden-
tified by previous GWAS for obesity and its related traits,
and examinedwhether these genes showeddifferentialDNA
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FIGURE 1
Flow chart describing the design of the multi-stage experiment. Note: AA = African-American; EA = European-American.
methylation between the obese and lean controls. Using this
approach,we successfully identified a repeatable association
of the DNA methylation level of one obesity GWAS gene
(LY86) with obesity. This is the first study to report the
association between LY86 gene methylation and obesity.
Materials and Methods
Study Design
The design of our multistage experiment is shown in
Figure 1. We first conducted a literature search for obesity
genes previously identified on DNA sequence variants. We
then mapped these genes on our initial genome-wide DNA
methylation panel (Illumina 27k chip) of seven obese cases
versus seven lean controls (i.e., the initial epigenome-wide
association studies [EWAS] panel). The CpG sites within
these genes showing differential methylation between cases
and controls with a raw p < .01 in this initial EWAS panel
were further checked for validation in our second genome-
wide DNA methylation panel (Illumina 450k chip) of 48
obese cases versus 48 lean controls (i.e., the second EWAS
panel). The CpG sites that survived the second EWAS panel
with a raw p < .01 were taken forward to the replication
stage. The replicated CpG site was further carried over to a
third stage, with the goal of examining the relationships of
the CpG sites with more accurate adiposity indices, as well
as obesity-related metabolic traits and inflammation in a
general population sample of youth.
Literature Search
We focused on three categories: (1)monogenic obesity, typ-
ically caused by a single gene mutation with severe early-
onset obesity as the main symptom; (2) syndromic obesity,
in which patients are clinically obese, yet are additionally
distinguishedbymental retardation andother developmen-
tal abnormalities; and (3) polygenic or common obesity,
which is likely caused by the interaction between numer-
ous genes and environmental factors (McCarthy, 2010).
The genetic bases for some of the extreme Mendelian hu-
man obesity (monogenic and syndromic) have been par-
tially or completely elucidated andwell reviewed previously
(Ramachandrappa & Farooqi, 2011). For polygenic obesity,
we included those genes reported in previous GWAS in
terms of obesity and obesity-related traits, including body
mass index (BMI), waist–hip ratio (WHR), waist circum-
ference (WC), and weight. The full gene list (N = 117) and
references are shown in Supplementary Table 1.
Study Subjects
Both the initial EWAS panel and the second EWAS panel
have been described previously (Wang et al., 2010; Xu et al.,
2013). Briefly, the initial EWAS panel included seven obese
and seven age-matched lean controls, all being African-
American (AA) males aged 14–18 years, living in the Au-
gusta, Georgia area. The obese cases had a BMI  99th
percentile and lean controls had a BMI  10th percentile
for age and gender. The second EWAS panel included 48
obese and 48 age- and gender-matched lean controls, all
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TABLE 1
General Characteristics of the Subjects
Initial EWAS Second EWAS Replication Replication
panel panel panel 1 panel 2
General population
Cases Controls Cases Controls Cases Controls Cases Controls panel
N 7 7 48 48 46 46 230 413 703
Males (%) 100 100 50 50 100 100 37.8 48.9 49.9
AAs (%) 100 100 100 100 100 100 58.3 39.7 47.1
Age (years) 15.8 ± 1.0 15.9 ± 1.4 17.5 ± 1.8 17.7 ± 1.8 20.3 ± 5.0 17.6 ± 3.1 20.6 ± 4.6 19.1 ± 3.9 16.2 ± 1.2
BMI(kg/m2) 39.0 ± 1.7 17.0 ± 0.7 42.0 ± 7.5 18.9 ± 1.3 37.4 ± 6.1 18.9 ± 1.2 35.8 ± 6.6 20.3 ± 2.2 22.9 ± 4.9
BMI percentile (%)∗ 99.6 ± 0.1 4.8 ± 2.2 99.2 ± 0.6 20.3 ± 11.1 98.6 ± 1.0 19.4 ± 9.4 97.5 ± 1.6 29.2 ± 14.2 60.4 ± 28.3
Note: EWAS = Epigenome-wide association studies; AAs = African-Americans; Means ± SD (range); ∗ BMI percentile for age and gender if age  18.
being AAs aged 14–20 years, and with 50% males. Obese
cases had a BMI  95th percentile and lean controls had a
BMI < 50th percentile for age and gender. There were two
replication panels. The first one included 46 obese (BMI
30 kg/m2 or BMI 95th percentile for age and gender if age
 18 years) and 46 lean (BMI  22 kg/m2 or BMI  40th
percentile for age and gender if age  18 years) youths; all
were AA males aged 14–30 years recruited from the same
area. The second replication panel included 230 obese (BMI
 30 kg/m2 or BMI 95th percentile for age and gender if
age  18 years) and 413 lean (BMI  25 kg/m2 or BMI 
50th percentile for age and gender if age 18 years) subjects
(aged 13–34 years) recruited from the same area, including
both AAs (N = 298) and European-Americans (EAs, N =
345), as well as males (N = 289) and females (N = 354).
There were no subjects overlapped among the initial EWAS
panel, the second EWAS panel, and two replications panels.
The third stage involved 703 subjects (aged 13–19 years,
372 EAs, 331 AAs, 351 males, and 352 females) with a BMI
ranging from 14.6 to 45.9 kg/m2, of which 12 subjects (six
obese vs. six lean) were included in the initial EWAS panel
(two subjects excluded here because no DNA was available
for this panel) and 221 subjects (53 obese vs. 168 lean) were
included in the replication stage. More detailed informa-
tion of the initial EWAS panel, the second EWAS panel,
the two replication panels, and the third panel is given in
the supplementary material. All subjects from these panels
were overtly healthy, free of any acute or chronic illness on
the basis of self-report and parental report (if subjects were
younger than 18 years), and were not on anti-hypertensive,
lipid lowering, anti-diabetic, or anti-inflammatory medi-
cations. The general characteristics are shown in Table 1.
The Institutional Review Board at the Medical College of
Georgia approved the studies. Written informed consent
was obtained from all subjects and by parents if subjects
were less than 18 years old.
Measurement of DNA Methylation
For all subjects, peripheral blood samples were collected
at the visit time. The buffy coat and plasma samples were
separated within two hours and stored at -80°C immedi-
ately.DNAwas extracted from thebuffy coat usingQiagen R©
QiAamp R© Blood Kit. TheHumanMethylation27 BeadChip
and the HumanMethylation450 BeadChip from Illumina
(San Diego, CA, USA) were used for the genome wide DNA
methylation profiling in the initial and the second EWAS
panels respectively, as described previously (Wang et al.,
2010; Xu et al., 2013). Themethylation levels of the selected
CpG sites for replicationswere determined by pyrosequenc-
ing technology (Wang et al., 2010), which is based on the
principle of sequencing by synthesis. For methylation anal-
ysis, pyrosequencing not only offers individual methylation
high-resolution results for all CpG sites, but also has built-
in control for bisulfite treatment to improve accuracy and
reproducibility. For eachCpG site, a 100–350-bp regionwas
amplified by polymerase chain reaction (PCR) using a pair
of primers complementary to the bisulfite-treated DNA se-
quence. Therefore, in addition to the targeted CpG site, the
pyrosequencing assaymay involve several surroundingCpG
sites.
Additional Measurements
A wide range of metabolic traits were measured in the
third panel (N = 703), including fasting glucose and in-
sulin levels, systolic and diastolic blood pressure (SBP and
DBP), plasma levels of total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), and triglyceride (TG), as well as fib-
rinogen and C-reactive protein (CRP). Insulin sensitivity
was assessed by quantitative insulin sensitivity check index
(QUICKI), calculated as:QUICKI=1/(Log (fasting insulin,
U/ml) + Log (fasting glucose, mg/dl)). In addition, more
accurate indices for adiposity as derived from dual-energy
X-ray absorptiometry (DEXA) scans, including visceral adi-
pose tissue (VAT), subcutaneous abdominal adipose tissue
(SAAT), and percentage of body fat (%BF), were also avail-
able in the same population (Gutin et al., 2007). Detailed
information is provided in the supplementary material.
Statistical Analyses
The genome wide methylation analysis has been described
previously (Wang et al., 2010; Xu et al., 2013). The Limma
package (Smyth, 2004) was used to analyze each CpG site
for differential methylation between the obese and lean
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TABLE 2
CpG Sites Selected From the Initial and the Second EWAS Panel
Methylation level (%)
Gene CpG site Cases Controls Difference p
Initial panela N = 7 N = 7
LEPR cg21655790 18.6 12.6 6.0 .002
SNRPN cg26033681 44.3 49.4 -5.1 .009
KREMEN1 cg01791232 23.7 18.1 5.6 .009
LY86 cg02212836 51.5 43.0 8.5 .009
Second panela N = 48 N = 48
LEPR∗ cg21655790 — — — —
SNRPN cg26033681 53.9 52.9 1.0 .169
KREMEN1 cg01791232 25.0 23.9 1.1 .028
LY86 cg02212836 58.4 54.7 3.7 .008
Note: aAdjusted for age in the initial panel and adjusted for age and gender in the second panel; ∗Not
included in the 450K chip.
subjects. Each CpG site was assigned a raw p value based
on a moderated t statistic. The successfully validated CpG
sites were further replicated in the second replication panel.
In this panel, linear regression was used to adjust for the
potential effects of age, gender, and race on methylation
levels. The gender × group (obese vs. lean) and race ×
group interaction terms were also built into the analyses to
test whether the observed methylation differences between
the obese and lean groups were race and gender dependent.
The weighted z score-based meta-analysis approach imple-
mented in the package METAL (Willer et al., 2010) was
used to combine the results from the two replication pan-
els, as well as the initial and the second EWAS panels. The
relationships of the validated CpG sites with more accurate
adiposity indices, as well as obesity-related metabolic traits
in the third panel, were examined by using partial corre-
lation analyses with adjustment for age, gender, and race.
As this panel included samples with pyrosequencing con-
ducted at different stages (221 samples at the second stage
and 482 samples at the third stage), the potential batch ef-
fect on themethylation levels of each CpG site was removed
by using linear regression and the residuals were used in
the partial correlation analyses. All statistical analyses were
performedusing STATA12 (StataCorp,College Station, TX,
USA) and p .05 is considered as significance.We also used
the program TFSEARCH to search for putative transcrip-
tion factor binding sites in this promoter region, which is
a simple routine searching highly correlated sequence frag-
ments versus TFMATRIX transcription factor binding site
profile database (Heinemeyer et al., 1998).
Results
A total of 117 genes were identified from the literature,
of which 89 genes were mapped onto the Illumina 27K
Beadchip. Four CpG sites showed significant differential
methylation between the obese and lean subjects (p < .01)
in the initial panel, located at the LEPR, SNRPN,KREMEN1
and LY86 genes (Table 2). In the second EWAS panel, only
the CpG site in LY86 gene showed significant differential
methylation between cases and controls with p < .01. In
both EWAS panels, the obese cases had higher methylation
levels of the CpG site in LY86 gene than the lean controls.
Pyrosequencing assays were designed to validate the asso-
ciation of this CpG site with obesity in the first replication
panel (46 obese vs. 46 lean controls). In addition to the
targeted CpG site, the pyrosequencing assays involved five
surrounding CpG sites. As shown in Table 3, the methyla-
tion level of the targeted CpG site was significantly higher
in the obese than that in the lean controls (56.7% vs. 52.2%,
p = .009). The methylation levels of the surrounding five
CpG sites varied from 20% to 50%, but always showed
higher methylation levels in the obese group in comparison
with the lean group. All six CpG sites of the LY86 gene were
further replicated in the second replication panel (230 obese
vs. 413 lean controls). After adjusting for age, gender, and
race, all six CpG sites showed significant highermethylation
levels in the obese compared to the controls (Table 3). No
significant interaction of obesity status with race or gen-
der was found on the methylation levels of these six CpG
sites. As expected, the meta-analysis with the EWAS panels
resulted in stronger associations of the methylation levels
with obesity (p= .00016 for LY86_5, the targeted CpG site).
In the general population panel, we found significant
positive correlations of the methylation levels of the LY86
gene with BMI, and additional indices of adiposity, in-
cluding %BF, VAT, and SAAT (Table 4). As the methy-
lation levels of these six CpG sites are highly correlated
(Pearson r > 0.8, Supplementary Table 2), we also per-
formed a principal component (PC) analysis to combine
the six CpG sites into one PC score (LY86_pc), which ex-
plained 90% of the variance for all six CpG sites. Simi-
larly, this component was significantly associated with all
four indices of adiposity, with the partial correlation co-
efficients being 0.096 (p = .01), 0.099 (p = .009), 0.138
(p = .004), and 0.109 (p = .02) for BMI, %BF, VAT, and
SAAT respectively, after adjusting for age, gender, race, and
batch. These results indicate that the association of LY86
gene methylation is consistent across different measures of
adiposity.
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TABLE 3
DNA Methylation of LY86 and Obesity in the Replication Panels
Methylation level (%)
Gene CpG site Cases Controls Difference p p (adjusted)a p (meta)b
Replication panel 1 N = 46 N = 46
LY86 LY86_1 41.8 38.1 3.7 .03 .08 —
LY86_2 44.2 39.0 5.2 <.001 .005 —
LY86_3 24.6 20.8 3.8 .001 .009 —
LY86_4 56.1 51.5 4.6 .008 .05 —
LY86_5∗ 56.7 52.2 4.5 .009 .05 —
LY86_6 51.4 46.8 4.6 .003 .03 —
Replication panel 2 N = 230 N = 413
LY86 LY86_1 44.3 42.4 1.9 .002 .01 .003
LY86_2 46.3 44.6 1.7 .002 .01 <.001
LY86_3 24.8 23.5 1.3 .003 .02 .001
LY86_4 49.3 47.0 2.3 .001 .01 .002
LY86_5∗ 49.7 47.7 2.0 .006 .03 .007
LY86_6 51.9 49.7 2.2 .001 .02 .004
Note: ∗LY86_5 is the targeted CpG site cg02212836; aAdjusted for age in the replication panel 1 and adjusted for age, gender, and race in the replication
panel 2; bMeta analysis on the replication panels 1 (age-adjusted) and 2 (age-, gender- and race-adjusted).
TABLE 4
Associations of Methylation Levels of the LY86 Gene With Body Mass Index and Additional Indices for Adiposity in the Third
Panel (N = 703) Representing the General Population of Youth
BMI % body fat VATb SAATb
CpG Partial Partial Partial Partial
sitesa correlationc p correlationc p correlationc p correlationc p
LY86_1 .131 <.001 .138 <.001 .147 .002 .130 .006
LY86_2 .100 .008 .097 .01 .151 .001 .137 .004
LY86_3 .089 .02 .090 .02 .120 .01 .105 .03
LY86_4 .094 .01 .087 .02 .126 .008 .094 .05
LY86_5 .088 .02 .093 .01 .137 .004 .097 .04
LY86_6 .067 .08 .077 .04 .127 .008 .085 .08
LY86_pc1d .096 .01 .099 .009 .138 .004 .109 .02
Note: BMI = body mass index; VAT = visceral adipose tissue; SAAT = subcutaneous abdominal adipose tissue; aAdjusted for batch; bLog-transformed;
cAdjusted for age, gender, and race; dThe first principal component score calculated based on the methylation levels of six CpG sites, adjusted
for batch.
We further examined the associations of themethylation
levels of theCpG siteswith several obesity-relatedmetabolic
traits and two inflammatory markers. As shown in Table 5,
the PC score of the six CpG sites was significantly associated
with fasting glucose (partial r = 0.107, p = .007), fasting
insulin (partial r = 0.123, p = .002), and insulin sensitivity
(partial r = -0.129, p = .001), as well as fibrinogen (partial
r = 0.167, p < .001) and CRP (partial r = 0.147, p <
.001), after adjusting for age, gender, race, and batch. These
associations attenuated somewhat, but remained significant
after further adjustment for BMI, indicating that part of
the effects of LY86 gene methylation on insulin resistance
and inflammation are independent of body weight. The
associations of the metabolic traits with the six individual
CpG sites were similar to the results obtained from the PC
score (Supplementary Table 3).
To further elucidate the role ofmethylation in this region
on potential function of the LY86 gene, we performed an in
silico analysis of the region, including these six CpG sites
(122 bases), using TFSEARCH software (Heinemeyer et al.,
1998; Figure 2). There were 21 transcription factor-binding
sites that passed the threshold (score > 85.0), of which 12
could be found in humans. Interestingly, the third CpG
site is located in a region potentially binding with many
transcription factors, including USF, c-Myc, and Max. The
sixth CpG site is within a binding site for AML-1a. These
results indicate that methylation of these CpG sites may
affect gene expression by blocking these transcription factor
binding sites.
Discussion
Taking advantage of our previous genome-wide methy-
lation profiling on obesity (Wang et al., 2010; Xu et al.,
2013), in this study we aimed to integrate this data with
a hypothesis-based list of obesity genes based on evidence
frommonogenic, syndromic, and common obesity. Among
the 89 GWAS genes mapped on the Illumina 27K methy-
lation platform, the higher methylation level of the LY86
gene in obese cases was successfully confirmed in another
genome-widemethylationpanel and two replicationpanels.
In a well-phenotyped general population cohort of youth,
we further showed that LY86 genemethylation was not only
associated with all adiposity indices but also with insulin
TWIN RESEARCH AND HUMAN GENETICS 187
https://www.cambridge.org/core/terms. https://doi.org/10.1017/thg.2014.22
Downloaded from https://www.cambridge.org/core. University of Groningen, on 30 Oct 2018 at 15:00:08, subject to the Cambridge Core terms of use, available at
Shaoyong Su et al.
TABLE 5
Associations of Methylation Levels of the LY86 gene (LY86_pc) with the
Obesity-Related Metabolic Traits and Inflammatory Markers in the Third Panel (N =
703) Representing the General Population of Youth
LY86_pcb
Model 1c Model 2d
Metabolic Partial Partial
traitsa correlation p correlation p
Fasting glucose .094 .02 .082 .04
Fasting insulin .121 .002 .086 .03
QUICKI -.124 .002 -.091 .02
SBP .092 .02 .067 .08
DBP .072 .06 .068 .08
TC .030 .44 .024 .55
HDL-C -.058 .14 -.032 .41
LDL-C .064 .10 .048 .22
TG .050 .21 .025 .52
Fibrinogen .170 <.001 .145 <.001
CRP .143 <.001 .114 .005
Note: aAll traits are log-transformed except QUICKI and DBP; bThe first principal component score
calculated based on the methylation levels of six CpG sites, adjusted for batch; cAdjusted for
age, gender and race; dAdjusted for age, gender, race and BMI.
FIGURE 2
TFSEARCH search result of the six CpG sites (underlined) in the promoter region of the LY86 gene (122 bases). There were 21 transcription
factor binding sites that passed the threshold (score >85.0), of which 12 could be found in human. Interestingly, the third CpG site is
located in a region potentially binding with many transcription factors, including USF, c-Myc, and Max. The sixth CpG site is within a
binding site for AML-1a.
resistance and inflammation markers, indicating that LY86
gene methylation may also play a role in obesity-related
metabolic disorders.
The protein encoded by the LY86 gene is the ‘lympho-
cyte antigen 86’, also known as protein MD-1, which is
a secreted glycoprotein physically associated with RP105
(a toll-like receptor (TLR) family protein) and playing a
crucial role in B cell surface expression of RP105 (Nagai
et al., 2002). The RP105/MD-1 complex is expressed on
immune cells, including B cells, macrophages, and den-
dritic cells. Mice deficient in either RP105 or MD-1 ex-
hibit reduced lipopolysaccharide (LPS) responsiveness in B
cells (Nagai et al., 2002; Ogata et al., 2000). On the other
hand, the expression of RP105/MD-1 in dendritic cells and
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macrophageshas been shown to serve as anegative regulator
of TLR4/MD-2 in the LPS response (Divanovic et al., 2005).
Growing evidence suggests that LY86may be involved in the
(patho)physiological regulation of the innate immune sys-
tem and inflammation (Sasaki et al., 2012). Most recently,
in a mice model, Watanabe et al. (2012) reported that MD-
1 may contribute to high-fat, diet-induced obesity, adipose
tissue inflammation, and insulin resistance.
Whether the expression of the LY86 gene is regulated by
DNAmethylation remainsunknown.According to themost
recent release of Genome Browser, the CpG sites showing
higher methylation levels in the obese subjects from the
current study are located in the first exon with a distance of
61–133 bp (first and sixth CpG sites) to the transcription
start site. Further in silico analysis of this region revealed
that the third and sixth CpG sites are located at known
binding sites for several transcription factors. For example,
USF expression has been associated with metabolic traits in
mice, including obesity, plasma lipid, and glucose/insulin
ratio (Wu et al., 2010). In addition, the same study showed
that binding of this factor to its DNA target is controlled
by the methylation level of a single CpG dinucleotide in-
cluded in its targeted sequence. Similarly, c-Myc binds its
target sequence in a methylation-dependent manner, and
over-expression of c-Myc in the liver has been reported to
prevent obesity and insulin resistance in mice (Riu et al.,
2003). The enrichment of transcription binding sites in
this region and the methylation-dependent binding man-
ner provide a possibility that methylation of these CpG
sites in the LY86 gene may alter gene expression by block-
ing transcription factor binding. Transcriptional profiling
studies in peripheral blood leukocytes may provide some
evidence on the relationship between LY86 gene methyla-
tion and gene expression.We searched the Gene Expression
Omnibus (GEO) database and identified a dataset (Ghosh
et al., 2010; GSE18897) that included genome-wide gene
expression data in peripheral blood samples from 20 obese
and 20 lean adults. In line with our findings that obese cases
had higher methylation levels of the LY86 gene, in this gene
expression dataset, the expression level of LY86 gene was
lower in the obese cases than in the lean controls, although
the difference did not reach significance (309 ± 78 vs.
340 ± 75, p = .18).
The fact that LY86 is one of the GWAS-identified genes
for obesity traits raised a possibility that the observed
methylation difference between obese cases and lean con-
trols may result from the obesity-associated single nu-
cleotidepolymorphisms (SNPs).TheGWAS-identifiedSNP
is rs1294421, which is associated with WHR (adjusted for
BMI) and is located 87kb from the LY86 gene. Data on both
the genotype of this SNP and LY86 gene methylation are
available in 345 of the current study samples. We did not
observe the genotype of this SNP was associated with the
methylation levels of these CpG sites (data not shown), in-
dicating that the observed methylation difference between
cases and controls is not caused by this SNP. However, we
cannot exclude the possibility that other genetic variants in
or near LY86 gene may influence the methylation levels of
these CpG sites.
There are several strengths to this study. First, by focus-
ing on youth and young adults at a pre-disease stage, we
were optimizing chances to detect disease-specific epige-
netic alterations, as presumably they are not yet masked
by the background of age-related and medication-arising
epigenetic ‘drift’ (Groom et al., 2011). Second, the two
replication panels, with large samples recruited from the
same area, enabled us to replicate the initial findings not
only in AA males, but also in EAs and females. As shown
in the result section, we did not observe significant inter-
actions between obesity status and race or gender on the
methylation levels of LY86 gene. Further stratified analyses
by race and gender revealed similar significant findings in
EAs (p = .001) and females (p = .003). In addition, involv-
ing the third panel enables us to extend our findings to a
general population of youth. Third, the approach of inte-
grating previous genomic and epigenomic data may help
in prioritizing the signals for further validation. Our ap-
proach of replicating candidate genes is hypothesis driven,
thus not requiring the same multiple testing penalty as the
genome-wide approach.
This studyalsohas some limitations. First, epigenetic reg-
ulation is tissue specific. In this regard, the target tissue to
identify epigenetic variations responsible for obesity should
preferably be adipose tissue or the hypothalamus. However,
there is increasing evidence that biomarkers derived from
blood may provide an alternative to tissue biopsy for the
diagnosis and prognosis of disease (Dzau & Liew, 2007).
In addition, obesity is multifactorial in origin and several
organs have been implicated in metabolic regulation. In re-
cent years, compelling evidence has emerged pointing to
the involvement of low-grade inflammation in the patho-
physiology of obesity and suggests that the immune system
might be the missing mechanism that links these various
organs with peripheral blood leukocytes as an important
mediator (Pradhan, 2007). Furthermore, methylation pro-
files are typically established during early developmental
stages prior to major cell differentiation, and subsequently
maintained through cell divisions (Petronis, 2010). Thus,
individual-specific, disease-related methylations may ap-
pear not only in the affected tissue(s), but across the human
body, including accessible tissues such as blood. In this case,
to interpret the function of the current finding on LY86 gene
methylation, it will be necessary to conduct gene expression
analysis not only in peripheral blood cells but also in adi-
pose and hypothalamic or other organs implicated in the
metabolic regulation of obesity. Second, we used the DNA
from leukocytes, which represent different cell populations
with distinct epigenetic profiles. A potential concern is that
the results might be biased if the case group and control
group display different cell compositions. Recently, a series
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of studies (Houseman et al., 2012; Koestler et al., 2012; Liu
et al., 2013; Reinius et al., 2012) were conducted to address
this concern by identifying differentially methylated CpG
sites among leukocyte subtypes (including CD4+ T cells,
CD8+ T cells, CD56+ NK cells, B cells, monocytes and
granulocytes) as well as using these CpG sites to predict
the cell compositions and adjusting them in the data analy-
sis. The LY86 gene CpG site is within the top 500 CpG sites
showingdifferentialmethylation among leukocyte subtypes
(Supplementary Figure 1; Koestler et al., 2012). We pre-
dicted the cell compositions for both the initial and the
second EWAS panels using Houseman’s algorithm (House-
man et al., 2012) and observed that the obese group had a
higher percentage of granulocytes in the initial panel and
a lower percentage of natural killer (NK) cells in both the
initial and the second genome-wide panels (Supplemen-
tary Tables 4 and 5). We conducted further analysis in the
second genome-wide panel adjusting for the predicted cell
compositions using linear regression models as suggested
by Liu et al. (2013) and observed that this CpG site showed
an even stronger association with obesity status (p = 3.49
× 10−7, Supplementary Table 6), indicating that our sig-
nificant finding on the LY86 gene was not caused by shifts
in these leukocyte subpopulations. Due to the limited sam-
ple size of the first panel (seven cases vs. seven controls)
and the request of five covariates for the adjustment of cell
compositions, we did not conduct this analysis in the first
panel because we did not have enough sample size to pro-
vide reliable correlation estimates. Future studies on DNA
methylation profiling of various types of cell populations of
leukocytes are warranted to gain a greater understanding of
the epigenetic dysregulation in obesity.
In conclusion, by focusing on previous genomic find-
ings on monogenic, syndromic, and common obesity in
our genome-wide methylation profiling, for the first time
we identified a solid association between LY86 gene methy-
lation and obesity in three stages with over 1,000 samples.
Further studies are warranted to determine the functional
meaning of such methylation changes. Such studies will
have the ability to identify new insight into disease etiology
and provide new targets for prevention of obesity related
diseases such as CVD and T2D.
Supplementary Material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/thg.2014.22.
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